For new targets of retinal disease, anti-CD146 therapy combined with anti-VEGF therapy enhances the damage induced by hypoxia-induced angiogenesis in vitro and in vivo because under hypoxic conditions, CD146 is involved in the activation of the NF-κB, extracellular regulated protein kinase (ERK), and AKT signaling pathways [174]. Here, MCAM is linked to Abnormal retinal morphology.